Physician profile
Brynae Miley
NPI 1699986992
$3,539.11
in general payments reported to CMS, 2019-2025
28 companies · $852 in 2025
The $852 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $184 · 2021: $354 · 2022: $447 · 2023: $514 · 2024: $938 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827 · Travel and Lodging: $443 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.81 |
| Travel and Lodging | $442.66 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $567.52 | 2020-2025 | |
| Inspire Medical Systems, INC. | $561.14 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $517.99 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $381.27 | 2019-2025 | Dupixent |
| Kaleo, INC. | $324.03 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $319.62 | 2021-2025 | |
| Stryker Corporation | $149.99 | 2019-2021 | |
| Integra Lifesciences Corporation | $147.57 | 2023-2025 | Integra, Integra Duo, Instruments-Orthopedic |
| Ars Pharmaceuticals Operations, INC. | $58.53 | 2025 | Neffy |
| Phathom Pharmaceuticals, INC. | $57.67 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $55.97 | 2019-2025 | Keytruda |
| Amgen INC. | $49.19 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $40.63 | 2025 | Tezspire |
| Aerin Medical INC. | $39.06 | 2019-2023 | |
| Neurent Medical Limited | $36.07 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $34.26 | 2020-2023 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Intersect Ent, INC. | $28.88 | 2019-2022 | |
| Smith+Nephew, INC. | $19.76 | 2019 | |
| Axogen | $18.25 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.17 | 2025 | Xhance |
| Acclarent, INC | $16.19 | 2023 | Acclarent Aera, Relieva Scout, Relieva Spinplus |
| Ambu INC. | $15.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.80 | 2021 | |
| Hikma Pharmaceuticals USA | $14.19 | 2024 | Ryaltris |
| Arbor Pharmaceuticals, INC. | $13.99 | 2019 | |
| Covidien LP | $13.59 | 2020 | |
| Alk-Abello, INC | $12.76 | 2020 | |
| Olympus America INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brynae Miley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.